Xenon Pharmaceuticals Inc.
XENE
Rang in Aktien
#4655
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company... Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development. Beyond its internal development, Xenon Pharmaceuticals has established strategic collaborations. This includes a licensing and development agreement with Neurocrine Biosciences, Inc. focused on epilepsy treatments, and a partnership with Flexion Therapeutics, Inc. to advance PCRX301 (also known as XEN402), a Nav1.7 inhibitor, for post-operative pain management. Established in 1996, the company continues its mission to address significant unmet medical needs in neurology.
Aktienkurs
$33.60
Zuletzt synchronisiert: 2026-10-16
Marktkapitalisierung
$3.25B
Veränderung (1 Tag)
-2.13%
Veränderung (1 Jahr)
-19.29%
Land
CA
Handel Xenon Pharmaceuticals Inc. (XENE)
Kategorie
Healthcare
EPS für Xenon Pharmaceuticals Inc. (XENE)
EPS zum June 2026 TTM: $-4.74
Laut den aktuellen Finanzberichten und dem Aktienkurs von Xenon Pharmaceuticals Inc. beträgt das aktuelle EPS des Unternehmens (TTM) $-4.74. Am Ende des Jahres 2023 betrug das EPS $-2.73 eine Steigerung gegenüber dem EPS von 2022, das $-2.06 betrug.
EPS-Verlauf von Xenon Pharmaceuticals Inc. von 2011 bis 2026
EPS am Ende jedes Jahres
| Jahr | EPS | ändert |
|---|---|---|
| 2026 (TTM) | $-4.74 | 57.48% |
| 2024 | $-3.01 | 10.26% |
| 2023 | $-2.73 | 32.52% |
| 2022 | $-2.06 | 16.38% |
| 2021 | $-1.77 | 113.25% |
| 2020 | $-0.83 | -46.10% |
| 2019 | $-1.54 | -13.48% |
| 2018 | $-1.78 | 4.09% |
| 2017 | $-1.71 | 15.54% |
| 2016 | $-1.48 | 34.55% |
| 2015 | $-1.10 | -217.02% |
| 2014 | $0.94 | 123.81% |
| 2013 | $0.42 | -113.00% |
| 2012 | $-3.23 | -64.19% |
| 2011 | $-9.02 | 0.00% |
EPS für ähnliche Unternehmen oder Wettbewerber
| Unternehmen | EPS | EPS-Differenz | Land |
|---|---|---|---|
| $17.32 | -465.40% |
US
|
|
| $-7.98 | 68.35% |
US
|
|
| $-5.29 | 11.60% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -685.23% |
NL
|
